title: Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.
abstract: The penetration of 3'-amino-3'-deoxythymidine (AMT) into the cerebrospinal fluid (CSF) of HIV-1-infected patients has been investigated. In 23 patients who used zidovudine (ZDV) chronically, CSF and plasma samples were assayed for AMT and ZDV. The influences of time between ZDV oral administration and lumbar puncture, of ZDV dose, and of the medical indication for lumbar puncture based on the concentration of AMT in CSF and on the CSF-plasma concentration ratio were investigated. AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml). The median CSF-plasma concentration ratio was 1, and equaled that for ZDV. CSF and plasma concentrations of AMT were approximately threefold higher in patients with cerebral toxoplasmosis; the CSF-plasma concentration ratio remained equal to unity in these cases. This phenomenon might be caused by a pharmacokinetic interaction between AMT and pyrimethamine, sulfadiazine, folinic acid, or a combination of these. The clinical relevance of AMT, especially the possibility of decreased efficacy of ZDV, throughout the body and in the central nervous system, and the involvement of this metabolite in ZDV-induced myelosuppression, remains to be established.
authors.affiliation: Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands.
authors.forename: R M
authors.initials: RM
authors.lastname: Hoetelmans
authors.forename: C L
authors.initials: CL
authors.lastname: Kraaijeveld
authors.forename: P L
authors.initials: PL
authors.lastname: Meenhorst
authors.forename: J W
authors.initials: JW
authors.lastname: Mulder
authors.forename: D M
authors.initials: DM
authors.lastname: Burger
authors.forename: C H
authors.initials: CH
authors.lastname: Koks
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism; D000890:Anti-Infective Agents / Q000493:pharmacokinetics; D000931:Antidotes / Q000493:pharmacokinetics; D015224:Dideoxynucleosides / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D002955:Leucovorin / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000493:pharmacokinetics; D013129:Spinal Puncture; D013411:Sulfadiazine / Q000493:pharmacokinetics; D013997:Time Factors; D016781:Toxoplasmosis, Cerebral / Q000097:blood / Q000134:cerebrospinal fluid; D015215:Zidovudine / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism
chemical_list: D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D000931:Antidotes; D015224:Dideoxynucleosides; D013411:Sulfadiazine; D015215:Zidovudine; C019252:3'-aminothymidine; D002955:Leucovorin; D011739:Pyrimethamine